StockData
Perspective Therapeutics, Inc. logo

Perspective Therapeutics, Inc. (CATX) stock

CATXNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$0.75−0.03 (-3.85%)

Close on Nov 20, 2026Market cap $86.05MP/E –Yield –

Perspective Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Perspective Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$121.18M. For fiscal 2025 it was -$110.31M. The highest annual figure on record is -$2.07M in fiscal 2011.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$110.31M–
FY2024Dec 31, 2024-$88.58M–
FY2017Jun 30, 2017-$6.24M–
FY2016Jun 30, 2016-$4.61M–
FY2015Jun 30, 2015-$3.76M–
FY2014Jun 30, 2014-$3.90M–
FY2013Jun 30, 2013-$3.33M–
FY2012Jun 30, 2012-$2.75M–
FY2011Jun 30, 2011-$2.07M–

Quarterly ebitda

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026-$28.12M–
Q1 FY2026CQ1 2026Mar 31, 2026-$27.16M–
Q4 FY2025CQ4 2025Dec 31, 2025-$38.82M–
Q3 FY2025CQ3 2025Sep 30, 2025-$27.09M–
Q2 FY2025CQ2 2025Jun 30, 2025-$23.31M–
Q1 FY2025CQ1 2025Mar 31, 2025-$21.10M–
Q4 FY2024CQ4 2024Dec 31, 2024-$44.28M–
Q3 FY2024CQ3 2024Sep 30, 2024-$17.97M–
Q2 FY2024CQ2 2024Jun 30, 2024-$13.69M–
Q1 FY2024CQ1 2024Mar 31, 2024-$12.65M–
Q4 FY2022CQ2 2022Jun 30, 2022-$2.03M–
Q3 FY2022CQ1 2022Mar 31, 2022-$1.30M–
Q4 FY2017CQ2 2017Jun 30, 2017-$1.85M–
Q3 FY2017CQ1 2017Mar 31, 2017-$1.37M–
Q2 FY2017CQ4 2016Dec 31, 2016-$1.46M–
Q1 FY2017CQ3 2016Sep 30, 2016-$1.56M–
Q4 FY2016CQ2 2016Jun 30, 2016-$1.20M–
Q3 FY2016CQ1 2016Mar 31, 2016-$1.19M–
Q2 FY2016CQ4 2015Dec 31, 2015-$1.27M–
Q1 FY2016CQ3 2015Sep 30, 2015-$954.00K–
Q4 FY2015CQ2 2015Jun 30, 2015-$967.79K–
Q3 FY2015CQ1 2015Mar 31, 2015-$916.94K–

More Perspective Therapeutics figures

See a number that looks wrong?